Aardvark Therapeutics, Inc. (AARD)
| Market Cap | 29.76M -88.0% |
| Revenue (ttm) | n/a |
| Net Income | -69.89M |
| EPS | -3.20 |
| Shares Out | 21.88M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 467,601 |
| Open | 1.390 |
| Previous Close | 1.440 |
| Day's Range | 1.330 - 1.460 |
| 52-Week Range | 0.930 - 16.600 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 7.50 (+451.47%) |
| Est. Earnings | Nov 12, 2026 |
About AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for AARD stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 451.47% from the latest price.
News
Aardvark Therapeutics price target lowered to $10 from $19 at Jones
Jones lowered the firm’s price target on Aardvark Therapeutics (AARD) to $10 from $19 and keeps a Buy rating on the shares. The firm cites delays in Prader-Willi syndrome program…
Aardvark Therapeutics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Leland Gershell downgraded Aardvark Therapeutics (AARD) to Perform from Outperform without a price target The company announced the lift of ARD-101’s clinical hold and reported exp...
Aardvark Therapeutics price target lowered to $2 from $4 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Aardvark Therapeutics (AARD) to $2 from $4 and keeps a Neutral rating on the shares following the lifting of…
Aardvark Therapeutics price target lowered to $1.50 from $4 at BofA
BofA lowered the firm’s price target on Aardvark Therapeutics (AARD) to $1.50 from $4 and keeps an Underperform rating on the shares following the clinical hold on ARD-101. The firm…
Aardvark Therapeutics price target lowered to $2.50 from $6 at RBC Capital
RBC Capital lowered the firm’s price target on Aardvark Therapeutics (AARD) to $2.50 from $6 and keeps a Sector Perform rating on the shares.
Aardvark Therapeutics Transcript: FDA announcement
FDA lifted the ARD-101 clinical hold after lower-dose testing showed no QRS or QT prolongation. Early HERO and OLE results showed exploratory efficacy signals, and a new Phase 3 design will be discussed with FDA.
Aardvark Therapeutics Press release: FDA announcement
Aardvark Therapeutics issued a press release on October 23, 2026, disclosing material business information to investors.
Aardvark Therapeutics Slides: FDA announcement
Aardvark Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 23, 2026.
Aardvark Therapeutics reports exploratory efficacy data from HERO trial
Aardvark Therapeutics (AARD) reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective, or HERO, trial and open-label extension, or OLE, trial...
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
SAN DIEGO, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeut...
Aardvark Therapeutics Inc trading resumes
16:35 EDT Aardvark Therapeutics (AARD) Inc trading resumes
FDA lifts hold on Aardvark Therapeutics IND application for ARD-101
Aardvark Therapeutics (AARD) announced that the FDA has lifted the clinical hold on the company’s investigational new drug application for ARD-101 for the treatment of hyperphagia in PWS. On February…
Aardvark Therapeutics Inc trading halted, news pending
16:01 EDT Aardvark Therapeutics (AARD) Inc trading halted, news pending
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
Clinical development of ARD-101 for hyperphagia in Prader-Willi Syndrome (PWS) may resume Aardvark will host a webcast to review available dataset from the terminated Phase 3 HERO trial and OLE trial ...
Aardvark Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Aardvark Therapeutics (AARD) to $4 from $6 and keeps a Neutral rating on the shares. The firm says the full clinical hold…
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 13, 2026 in Aardvark Therapeutics, Inc. Lawsuit - AARD
A securities class action alleges Aardvark Therapeutics' SEC filings warned about clinical risk in generic terms while describing ARD-101 as "99% restricted to the gut" with "no serious adverse events...
Aardvark Therapeutics Appoints Clinical Development Leader David Zhang, Ph.D., MBA, to its Board of Directors
Brings more than 25 years of experience in clinical strategy, biostatistics and regulatory submissions from Abivax, Alumis, MyoKardia and Genentech/Roche
If You Lost Money Investing in Aardvark Therapeutics, Inc. (AARD) Contact Robbins LLP for Information About Recovering Your Losses
San Diego, California--(Newsfile Corp. - October 5, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased ...
Aardvark Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (Aardvark) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics ...
AARD Stock News: Robbins LLP Reminds Aardvark Therapeutics, Inc. Stockholders to Contact the Firm Before the October 13, 2026 Lead Plaintiff Deadline
SAN DIEGO, Sept. 30, 2026 /PRNewswire/ -- Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise acqui...
Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws
NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C.
Robbins LLP is Investigating Allegations that Aardvark Therapeutics, Inc. Misled Investors Regarding the Viability and Efficacy of its Lead Drug Candidate ARD-101
San Diego, California--(Newsfile Corp. - September 17, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchas...
AARD Stockholders Have Rights – If You Lost Money Investing in Aardvark Therapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO--(BUSINESS WIRE)---- $AARD #Aardvark--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise...
AARDVARK THERAPEUTICS, INC. (AARD) INVESTOR ALERT Investors With Large Losses in Aardvark Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
New York, New York--(Newsfile Corp. - August 18, 2026) - Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the "Class") who purcha...
Aardvark Therapeutics reports Q2 EPS (66c), consensus (88c)
As of June 30, Aardvark had cash, cash equivalents and short-term investments of $73.9M, compared to $91.2M as of March 31. Based on current operating plans, Aardvark believes that its…